Aim: This study aims to assess the effectiveness of aflibercept in patients with macular edema caused by Branch Retinal Vein Occlusion following dexamethasone implant treatment. Material and Methods: This study included treatment-naive 20 eyes of 20 patients. At baseline and follow-ups, the patients' Best Corrected Visual Acuity, the Central Macular Thickness and Central Macular Volume measures taken with Spectral-Domain Optical Coherence Tomography were recorded. The patients who had

more »

... ion of visual acuity or macular thickness ≥ 300 were administered intraocular injection again. Recurrent cases following dexamethasone injection were administered aflibercept injection three times with an interval of one month. Results: Compared to the baseline, the patients demonstrated an increase in visual acuity and a decrease in macular thickness and macular volume following the dexamethasone injection ( p=0.013, p=0.009, p=0.021, respectively). In an average of three and half months after the injection, there was a decrease in visual acuity (0.90 ± 0.44 logMAR), an increase in macular thickness (579 ± 107 μm) and macular volume (12.25 ± 1.55 mm3) (p>0.05 all). Three months after the the completion of three aflibercept injections, there was no deterioration in visual acuity (0.41 ± 0.23 logMAR) according to the recurrence time of macula edema (p=0.048). Macular thickness (288 ± 47 μm) and macular volume (8.59 ± 0.96 mm3) values demonstrated nonsignificant increases (p>0.05). Discussion: Aflibercept treatment is effective in recurrence following the Dexamethasone treatment in macula edema caused by branch retinal vein occlusion.